Alector | Therapies to Remember
Slide background

We are a biotech company dedicated to the discovery and development of first-in-class, disease-modifying, immuno-modulatory therapies for dementia and neurodegeneration.

Slide background

"Excellence is never an accident. It is always the result of high intention, sincere effort, and intelligent execution; it represents the wise choice of many alternatives – choice, not chance, determines your destiny.”
- Aristotle

Our Mission

To discover and develop first-in-class, disease-modifying,
immuno-modulatory therapies for dementia and neurodegeneration

About Alector

Alector is a hypothesis-driven, genetic-based, neuroscience company that discovers and develops therapeutics for Alzheimer’s disease and other forms of dementia and neurodegeneration. Our premise is that degenerative brain disorders are caused, in part, by a dysfunctional immune system. Therefore, we discover novel, immuno-modulatory drugs that harness the immune system to combat multiple disease pathologies. Conceptually, we are developing PD1 and CTLA4-like drugs for brain diseases. Our thesis is supported by new data of disease risk genes combined with the pathology of degenerative brain disorders. We are currently pursuing 12 drug targets and expect to be in clinical trials within 12-18 months. Alector has raised ~$80M from premier venture capitalists and pharmaceutical companies including OrbiMed, Polaris, Google Ventures, Merck, AbbVie, Amgen, and the Dementia Discovery Fund (consisting of the World Health Organization, UK Government, J&J, Pfizer, GSK, Biogen, Takeda, Lilly).

  • Amgen
  • OrbiMed
  • Polaris
  • Merck
  • AbbVie
  • Google
  • Topspin
  • Mission Bay Capital
  • DDFund
  • DDFund-Investors


Thought leaders in biotechnology, neuroscience, and antibody drug discovery

  • All
  • Board
  • Founders
  • SAB

Co-Founder, President, CSO, Board Member, Chairman of Scientific Advisory Board - Rinat Neuroscience Corp. (acquired by Pfizer in 2006)

Co-Founder, Board Member - Annexon Inc.

Member of Scientific Advisory Board - Simons Foundation Autism Research Initiative

Member of Scientific Advisory Board - Myelin Repair Foundation

Former Member of Scientific Advisory Board for Neuroscience - UCB Pharma

Executive Scientist, Member of the Research Review Committee - Genentech Inc.

Arnon Rosenthal, PhD
Co-Founder, CEO, President




Tillman Gerngross, PhD


Asa Abeliovich, MD PhD


Vice President - Pharmaceuticals Discovery, AbbVie

Adjunct Professor - Department of Pharmacology, Northwestern University

Vice President - Global Pharmaceutical Discovery, Abbott

James Sullivan, PhD
VP of Pharmaceutical Discovery - AbbVie

Associate Vice President and Head of Merck European Innovation Hub - Merck

Partner - MRL (Merck) Ventures

Partner - Partners Innovation Fund

CEO - Targanox

Reza Halse, PhD
Head of EU Innovation Hub - Merck

Board Member - SGC

Scientific Advisory Board Member - FutuRX

Chief Scientific Officer - Dementia Discovery Fund, SV Life Sciences

General Manager - Pharmaceutical Research Division, Takeda

Director and Site Head - GlaxoSmithKline

Senior Investigator - Neuroscience Research Labs, Merck

Tetsuyuki Maruyama (Paul Chapman), PhD
Former GM of Research - Takeda

Private Equity Partner - OrbiMed

Rishi Gupta, JD
Private Equity Partner - OrbiMed

Managing Director - Amgen Ventures

Director of Corporate Development - Exelixis (formerly X-Ceptor Therapeutics)

Director of Business Development - Aurora Biosciences

Janis Naeve, PhD
Managing Director - Amgen

Co-Founder - ShanaRX Pharmaceuticals

Postdoctoral Researcher - Genentech Inc.

Tenured Associate Professor - Taub Institute at Columbia University, Departments of Pathology and Neurology

Diplomate in Neurology - American Board of Psychiatry and Neurology

Asa Abeliovich, MD PhD
Co-Founder, SAB Member

Co-Founder, CEO - Adimab LLC

Co-Founder, Chairman of the Board - Arsanis Inc.

Co-Founder, Chairman of the Board - Avitide Inc.

Co-Founder, CSO - GlycoFi (acquired by Merck in 2006)

Professor of Bioengineering - Dartmouth College

Venture Partner - SV Life Sciences

Tillman Gerngross, PhD
Co-Founder, Chairman of the Board

Scientist - Sutro Biopharma

Postdoctoral Research Fellow and Research Associate - Memorial Sloan-Kettering Cancer Center, Department of Immunology

Doctoral Research Scientist - European Institute of Oncology (Italy) and University of Cambridge (UK)

Francesca Avogadri-Connors, PhD
Ben Barres

Chair - Neurobiology, Stanford University School of Medicine

Professor - Neurobiology, Stanford University School of Medicine

Professor - Neurology & Neurological Sciences, Stanford University School of Medicine

Member - Stanford Neurosciences Institute

Professor - Developmental Biology, Stanford University School of Medicine

Member - US National Academy of Sciences

Ben Barres, MD PhD
Member - National Academy of Sciences, Neurobiology Chair - Stanford Medicine

Associate Professor of Neurology - UCSF

Vera and John Graziadio Scholar in Alzheimer’s Disease Research - UCSF

Director of Alzheimer’s Disease and Frontotemporal Dementia Clinical Trials Program - Memory and Aging Center, UCSF

Adam Boxer, MD PhD
Associate Professor Neurology - UCSF

Founding Partner, Co-Head of Global Private Equity - OrbiMed

Senior Biotechnology Analyst - Mehta and Isaly

Fellow - The Rockefeller University

Carl Gordon, PhD CFA
Founding Partner, Head of PE - OrbiMed


Arnon Rosenthal, PhD

Senior Vice President and CSO - Pfizer

Vice President, Experimental Medicine - Pfizer

Associate Director Scientist - Rinat

Postdoctoral Fellow - Genentech

John Lin, MD PhD
Former Senior VP, CSO - Pfizer

Director of Manager Research - North Creek Advisors

Senior Associate - The Parthenon Group

Analyst - Dean & Company

Kelly Hackett

Lab Manager - Dartmouth College

10+ years experience working in academic and industrial labs

Experience in GMP environments

Helped set up 3 new labs from start to finish

Heather Jewell

MS, Biomedical Science, Concentration in Biotechnology - San Francisco State University

BS, Biochemistry and Molecular Biology - University of California, Davis

Helen Lam
Lewis Lanier

Professor - American Cancer Society

Chair - Department of Microbiology and Immunology, UCSF

Leader - Cancer, Immunity, and Microenvironment Program, UCSF Helen Diller Family Comprehensive Cancer Center

J. Michael Bishop, MD, Distinguished Professor - Microbiology and Immunology, UCSF

Lewis Lanier, PhD
Chair - Dept of Immunology at UCSF
Seung-Joo Lee

Staff Research Associate - University of California, Davis

Postdoctoral Associate - University of California, Davis

PhD Immunology - University of Connecticut Health Center

Seung-Joo Lee, PhD

Co-Founder, General Partner - Polaris Partners

Co-Founder - Inspire Pharmaceuticals, AIR, MicroCHIPS

Chairman of the Board - Thayer School of Engineering, Dartmouth College

Board Member - MIT’s The David H. Koch Institute for Integrative Cancer Research

Board Member - The Arthur Rock Center for Entrepreneurship at HBS

2005 Recipient - Albert Einstein Award for Outstanding Achievement in Life Sciences

Terry McGuire
Co-Founder, General Partner - Polaris
Bruce Miller

Center Director - Dementia Center, UCSF

A.W. and Mary Margaret Clausen Distinguished Professorship - Neurology, UCSF

Principal Investigator - Alzheimer’s Disease Research Center (NIH-sponsored)

Scientific Director - The John Douglas French Alzheimer’s Foundation

Bruce Miller, MD
Director of Dementia Center - UCSF

Postdoctoral Research Fellow - Gladstone Institute of Virology and Immunology

Doctoral Research - University of California Berkeley, Program in Cell and Molecular Biology

Research Technician - University of Utah, Department of Human Genetics

Kate Monroe, PhD

Graduate Research Assistant - University of North Carolina

Graduate Research Assistant - East Carolina University

PhD Chemistry - University of North Carolina, Chapel Hill

William Monteith, PhD

Postdoctoral Fellow - The Rockefeller University

Graduate Research Assistant - Northwestern University

Andrew Pincetic, PhD
Richard Scheller

Chief Science Officer & Head of Therapeutics - 23andMe

Executive Vice President of Research and Early Development - Genentech

Professor - Stanford University

Member - US National Academy of Sciences

Richard Scheller, PhD
CSO - 23andMe, Member - National Academy of Sciences

Postdoctoral Research Fellow and Research Associate - Stanford University, Department of Neurobiology

Postdoctoral Research Fellow - Rockefeller University

Doctoral Research Scientist - Rockefeller University and University of Hohenheim, Germany

Tina Schwabe, PhD

Co-Founder, Director of Finance & Operations - Avitide Inc.

Director of Finance & Operations - Arsanis Inc.

Bain Capital Ventures

McKinsey & Company

Founder - Bedrock Ventures

Jonathan Sheller

Research Fellow - National Institute of Health, Laboratory of Molecular Immunology

Postdoctoral Research Fellow - Washington University, Department of Pathology

Doctoral Research Scientist - Washington University and La Sapienza University of Rome, Department of Experimental Medicine

Ilaria Tassi, PhD
Robert Vassar

Professor in Cell and Molecular Biology - Feinberg School of Medicine, Northwestern University

Robert Vassar, PhD
Professor - Feinberg School of Medicine

OrbiMed is a leading investment firm dedicated exclusively to the healthcare sector, with over $15 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies. OrbiMed's team of more than 90 employees manages a series of private equity funds, public equity funds, royalty/debt funds and other investment vehicles. OrbiMed maintains its headquarters in New York City, with additional offices in San Francisco, Shanghai, Mumbai and Herzliya.


Polaris Partners invests in exceptional technology and healthcare companies across all stages of their life cycles. With offices in Boston, San Francisco, and Dublin, we partner globally with an unparalleled network of repeat entrepreneurs, top scientists and emerging innovators who are making significant contributions in their fields and vastly improving the way in which we live and work.

Polaris Partners

MRL Ventures Fund, LLC is the therapeutics-focused seed and early-stage corporate venture fund of Merck & Co., Inc. From our headquarters in Kendall Square, Cambridge and with offices in Mission Bay, San Francisco and Central London, MRL Ventures invests globally in innovative science and transformational therapeutics. We are a team of experienced life-sciences venture capital professionals committed to supporting great entrepreneurs in their quest to create value through building companies that have a meaningful impact on health and disease.

MRL Ventures

Google Ventures

Topspin Partners is a private equity firm that focuses on control investments in lower middle-market companies with $2 million to $10 million of EBITDA. We seek to acquire companies that are both defensible and differentiated – that is, (1) the business has characteristics that enable it to compete in the marketplace other than by simply lowering price and (2) its products or services provide a different and, in many cases, unique approach to addressing an existing market need.

Topspin Partners
Mission Bay Capital

Mission Bay Capital (MBC) is an independent, seed-stage venture firm focused on making pivotal investments in bioscience companies emerging from the San Francisco Bay Area. MBC combines experienced management and a stellar advisory board with access to life-science accelerator QB3’s entrepreneurial network: University of California researchers, scientific facilities, and incubators at five locations including the San Francisco flagship, QB3@953. MBC’s goal is to “enable awesome”—to help entrepreneurial scientists change the world.

Mission Bay Capital

Neurodegenerative Diseases



Americans living with




leading cause of death

in the US



direct cost of caring for

Alzheimer’s patients to US

Alzheimer’s disease is the most common form of dementia, affecting over 5 million people in the US alone. It is characterized by gradual mental deterioration, loss of memory, and eventually death (it is the 6th-leading cause of death in the US). AD is a high-profile disease with diagnosis incidence rates expected to rise rapidly due to demographic trends. 11% of those over 65 have been diagnosed with Alzheimer’s. There are currently no methods to prevent, cure, or meaningfully slow its progression. In 2011, the Alzheimer’s disease drug market was a $5.8B. It is expected to grow to $14.5B by 2020 (excluding novel treatments and all other forms of dementia). The cost of care for Alzheimer’s is estimated to grow from $203B in 2013, to $1.2T in 2050. Other forms of dementia including frontotemporal dementia, are less common, with 100K-200K patients in the US, and are thus considered orphan diseases. No therapeutics have been shown to alter the inexorable courses of these disorders.

What Others Are Saying About Alzheimer’s

It’s an epidemic, it’s on the rise, and currently there is no way to delay it, prevent it or cure it.

– Maria Carrillo, PhD (Alzheimer’s Association)

If dementia care were a country, it would be the world’s 21st largest economy, ranking between Poland and Saudi Arabia.

– Alzheimer’s Association

We’ve had great success in this country when we’ve decided to focus on a condition. We’ve done it with good research in heart disease, cancer and HIV, but we are in our infancy when it comes to Alzheimer’s research.

– Jennifer Weuve, MPH ScD (Assistant Professor, Rush Medical College)

Recent News